Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis

Barbara Kluve-Beckerman, Joyce Hardwick, Lijing Du, Merrill Benson, Brett P. Monia, Andrew Watt, Rosanne M. Crooke, Adam Mullick

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

AA amyloid patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We have begun to explore the potential application of antisense oligonucleotides (ASOs) to specifically suppress SAA production and thereby reduce amyloid deposition. Proof-of-concept experiments conducted in mice initially examined ASO ability to reduce serum levels of SAA during an acute inflammatory response. Peak SAA levels in ASO-treated mice were reduced as much as 65% relative to levels in saline-treated mice. The extent of suppression was dose-dependent and influenced by the time interval between ASO administration and inflammatory stimulation. Subsequent experiments tested whether ASO suppression of SAA was sufficient to mitigate amyloid deposition. Amyloidosis was induced by amyloid-enhancing factor and silver nitrate injection; ASO treatment was initiated 1 week later and continued 1× or 3× per week; inflammation was re-triggered by subsequent injection(s) of silver nitrate; mice were sacrificed after 45 weeks. Examination of tissues by Congo red staining and SAA/AA immunohistochemistry revealed consistently less amyloid in the organs of ASO-treated mice compared to saline-treated counterparts. These findings provide rationale for further investigation of SAA-specific ASOs as a potential therapy for AA amyloidosis.

Original languageEnglish
Pages (from-to)136-146
Number of pages11
JournalAmyloid
Volume18
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Serum Amyloid A Protein
Antisense Oligonucleotides
Amyloidosis
Amyloid
Silver Nitrate
Inflammation
Congo Red
Injections
Renal Insufficiency
Disease Progression
Immunohistochemistry
Staining and Labeling
Therapeutics

Keywords

  • AA amyloidosis
  • Antisense oligonucleotide
  • Mouse model
  • Serum amyloid A

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. / Kluve-Beckerman, Barbara; Hardwick, Joyce; Du, Lijing; Benson, Merrill; Monia, Brett P.; Watt, Andrew; Crooke, Rosanne M.; Mullick, Adam.

In: Amyloid, Vol. 18, No. 3, 09.2011, p. 136-146.

Research output: Contribution to journalArticle

Kluve-Beckerman, B, Hardwick, J, Du, L, Benson, M, Monia, BP, Watt, A, Crooke, RM & Mullick, A 2011, 'Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis', Amyloid, vol. 18, no. 3, pp. 136-146. https://doi.org/10.3109/13506129.2011.597464
Kluve-Beckerman, Barbara ; Hardwick, Joyce ; Du, Lijing ; Benson, Merrill ; Monia, Brett P. ; Watt, Andrew ; Crooke, Rosanne M. ; Mullick, Adam. / Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. In: Amyloid. 2011 ; Vol. 18, No. 3. pp. 136-146.
@article{82b05616d546449e8266710767224f6e,
title = "Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis",
abstract = "AA amyloid patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We have begun to explore the potential application of antisense oligonucleotides (ASOs) to specifically suppress SAA production and thereby reduce amyloid deposition. Proof-of-concept experiments conducted in mice initially examined ASO ability to reduce serum levels of SAA during an acute inflammatory response. Peak SAA levels in ASO-treated mice were reduced as much as 65{\%} relative to levels in saline-treated mice. The extent of suppression was dose-dependent and influenced by the time interval between ASO administration and inflammatory stimulation. Subsequent experiments tested whether ASO suppression of SAA was sufficient to mitigate amyloid deposition. Amyloidosis was induced by amyloid-enhancing factor and silver nitrate injection; ASO treatment was initiated 1 week later and continued 1× or 3× per week; inflammation was re-triggered by subsequent injection(s) of silver nitrate; mice were sacrificed after 45 weeks. Examination of tissues by Congo red staining and SAA/AA immunohistochemistry revealed consistently less amyloid in the organs of ASO-treated mice compared to saline-treated counterparts. These findings provide rationale for further investigation of SAA-specific ASOs as a potential therapy for AA amyloidosis.",
keywords = "AA amyloidosis, Antisense oligonucleotide, Mouse model, Serum amyloid A",
author = "Barbara Kluve-Beckerman and Joyce Hardwick and Lijing Du and Merrill Benson and Monia, {Brett P.} and Andrew Watt and Crooke, {Rosanne M.} and Adam Mullick",
year = "2011",
month = "9",
doi = "10.3109/13506129.2011.597464",
language = "English",
volume = "18",
pages = "136--146",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis

AU - Kluve-Beckerman, Barbara

AU - Hardwick, Joyce

AU - Du, Lijing

AU - Benson, Merrill

AU - Monia, Brett P.

AU - Watt, Andrew

AU - Crooke, Rosanne M.

AU - Mullick, Adam

PY - 2011/9

Y1 - 2011/9

N2 - AA amyloid patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We have begun to explore the potential application of antisense oligonucleotides (ASOs) to specifically suppress SAA production and thereby reduce amyloid deposition. Proof-of-concept experiments conducted in mice initially examined ASO ability to reduce serum levels of SAA during an acute inflammatory response. Peak SAA levels in ASO-treated mice were reduced as much as 65% relative to levels in saline-treated mice. The extent of suppression was dose-dependent and influenced by the time interval between ASO administration and inflammatory stimulation. Subsequent experiments tested whether ASO suppression of SAA was sufficient to mitigate amyloid deposition. Amyloidosis was induced by amyloid-enhancing factor and silver nitrate injection; ASO treatment was initiated 1 week later and continued 1× or 3× per week; inflammation was re-triggered by subsequent injection(s) of silver nitrate; mice were sacrificed after 45 weeks. Examination of tissues by Congo red staining and SAA/AA immunohistochemistry revealed consistently less amyloid in the organs of ASO-treated mice compared to saline-treated counterparts. These findings provide rationale for further investigation of SAA-specific ASOs as a potential therapy for AA amyloidosis.

AB - AA amyloid patients who experience disease progression and develop renal failure have not received sufficient benefit from agents that treat inflammation or infection. We have begun to explore the potential application of antisense oligonucleotides (ASOs) to specifically suppress SAA production and thereby reduce amyloid deposition. Proof-of-concept experiments conducted in mice initially examined ASO ability to reduce serum levels of SAA during an acute inflammatory response. Peak SAA levels in ASO-treated mice were reduced as much as 65% relative to levels in saline-treated mice. The extent of suppression was dose-dependent and influenced by the time interval between ASO administration and inflammatory stimulation. Subsequent experiments tested whether ASO suppression of SAA was sufficient to mitigate amyloid deposition. Amyloidosis was induced by amyloid-enhancing factor and silver nitrate injection; ASO treatment was initiated 1 week later and continued 1× or 3× per week; inflammation was re-triggered by subsequent injection(s) of silver nitrate; mice were sacrificed after 45 weeks. Examination of tissues by Congo red staining and SAA/AA immunohistochemistry revealed consistently less amyloid in the organs of ASO-treated mice compared to saline-treated counterparts. These findings provide rationale for further investigation of SAA-specific ASOs as a potential therapy for AA amyloidosis.

KW - AA amyloidosis

KW - Antisense oligonucleotide

KW - Mouse model

KW - Serum amyloid A

UR - http://www.scopus.com/inward/record.url?scp=80052224466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052224466&partnerID=8YFLogxK

U2 - 10.3109/13506129.2011.597464

DO - 10.3109/13506129.2011.597464

M3 - Article

VL - 18

SP - 136

EP - 146

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - 3

ER -